Unknown

Dataset Information

0

Malaria vaccine candidate based on Duffy-binding protein elicits strain transcending functional antibodies in a Phase I trial.


ABSTRACT: Reticulocyte invasion by Plasmodium vivax requires interaction of the Duffy-binding protein (PvDBP) with host Duffy antigen receptor for chemokines (DARCs). The binding domain of PvDBP maps to a cysteine-rich region referred to as region II (PvDBPII). Blocking this interaction offers a potential path to prevent P. vivax blood-stage growth and P. vivax malaria. This forms the rationale for development of a vaccine based on PvDBPII. Here we report results of a Phase I randomized trial to evaluate the safety and immunogenicity of recombinant PvDBPII formulated with glucopyranosyl lipid adjuvant-stable emulsion (GLA-SE). Thirty-six malaria-naive, healthy Indian male subjects aged 18-45 years were assigned into three cohorts corresponding to doses of 10, 25 and 50?µg of PvDBPII formulated with 5?µg of GLA-SE. Each cohort included nine PvDBPII/GLA-SE vaccinees and three hepatitis B control vaccine recipients. Each subject received the assigned vaccine intramuscularly on days 0, 28 and 56, and was followed up till day 180. No serious AE was reported and PvDBPII/GLA-SE was well-tolerated and safe. Analysis by ELISA showed that all three doses of PvDBPII elicited antigen-specific binding-inhibitory antibodies. The 50?µg dose elicited antibodies against PvDBPII that had the highest binding-inhibitory titres and were most persistent. Importantly, the antibody responses were strain transcending and blocked receptor binding of diverse PvDBP alleles. These results support further clinical development of PvDBPII/GLA-SE to evaluate efficacy against sporozoite or blood-stage challenge in controlled human malaria infection (CHMI) models and against natural P. vivax challenge in malaria endemic areas.

SUBMITTER: Singh K 

PROVIDER: S-EPMC6162314 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature

altmetric image

Publications


Reticulocyte invasion by <i>Plasmodium vivax</i> requires interaction of the Duffy-binding protein (PvDBP) with host Duffy antigen receptor for chemokines (DARCs). The binding domain of PvDBP maps to a cysteine-rich region referred to as region II (PvDBPII). Blocking this interaction offers a potential path to prevent <i>P. vivax</i> blood-stage growth and <i>P. vivax</i> malaria. This forms the rationale for development of a vaccine based on PvDBPII. Here we report results of a Phase I randomiz  ...[more]

Similar Datasets

| S-EPMC5470884 | biostudies-literature
| S-EPMC4856259 | biostudies-literature
| S-EPMC4749986 | biostudies-literature
| S-EPMC10475129 | biostudies-literature
| S-EPMC6102825 | biostudies-literature
| S-EPMC3330128 | biostudies-literature
| S-EPMC1087359 | biostudies-literature
| S-EPMC4896725 | biostudies-literature
| S-EPMC3911863 | biostudies-literature
| S-EPMC5485662 | biostudies-literature